Prompt antiretroviral therapy reduces HIV patient cancer risk

HIV patients have an increased risk of developing skin and mucosal cancers, even when HIV is no longer detectable in their blood due to antiretroviral therapy. Now researchers from the Medical University of Vienna, the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD) and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences have shown that the time of starting antiretroviral therapy can influence tumour development, with their results published in the journal Immunity.

HIV (human immunodeficiency virus) infects and destroys immune cells that carry a specific molecule (CD4 receptor) on their surface. Over the course of the disease, these CD4⁺ T cells are greatly depleted, and this is associated with an increased risk of infection. Antiretroviral therapy (ART) for HIV-infected patients inhibits viral replication and reduces the viral load to such an extent that HIV is no longer detectable in the blood; this once again increases the number of CD4⁺ T cells in the blood, thus normalising the patient’s susceptibility to infection.

That said, despite years of optimal and suppressive antiretroviral therapy, people with HIV are still at increased risk of developing skin and mucosal cancers. In particular, they have a higher risk of developing those forms of cancer caused by human papillomaviruses (HPV). The risk of HPV-associated anal cancer is as much as 36 times higher in HIV-infected men than in HIV-negative individuals.

The research group, led by Vienna’s Georg Stary, has now described a new mechanism for tissue-specific dysregulation of the immune response in HIV patients. According to Stary, “We found that there are differences in tissue-specific immune responses depending on whether antiretroviral therapy was started promptly after diagnosis of HIV infection or was delayed.”

Tissue-resident memory T cells of the skin and mucosa play an important role in this process: these are part of the immunological memory and available for a rapid and effective tissue immune response when an organism has previously had contact with a pathogen. In HIV patients who did not start antiretroviral therapy until some time after diagnosis, there was irreversible depletion of tissue-resident memory T cells in the skin and mucosa, despite high numbers of CD4⁺ T cells in the blood.

In contrast, this depletion of memory T cells can be prevented if antiretroviral therapy is started promptly. In addition, it was found that HIV patients with HPV-induced mucosal cancer have a reduced number of tissue-resident memory T cells in the mucosa. This might explain the greater prevalence and more severe disease progression of HPV-associated tumours in people with HIV.

“The results of the study show the major importance of tissue-resident immune cells in the development of skin and mucosal cancers in HIV patients,” Stary said. “Furthermore, the findings may also have implications for other patients at increased risk of developing skin and mucosal cancers and similar phenomena could play a role, for example, in patients who are immunosuppressed following organ transplantation.”

Image credit: ©stock.adobe.com/au/Naeblys

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.